Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Aristotle University Of Thessaloniki
With
424 General Military Hospital
Age
40–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
postmenopausal women aged \> 40 years
diagnosis of osteoporosis, or osteopenia and Fracture Assessment Risk (FRAX) score indicative for initiation of anti-osteoporotic treatment, or osteopenia and history of low-energy fracture. Evaluation of osteopenia and osteoporosis will be based on bone mineral density (BMD) of the lumbar spine and/or the femoral neck of the non-dominant hip measured with dual energy X-ray absorptiometry (DXA)
diagnosis of NAFLD based on non-invasive indices of hepatic steatosis
written informed consent
You may not be if
mean ethanol consumption \>10 g/day
a history of other chronic liver disease (e.g., viral hepatitis, autoimmune hepatitis, primary sclerosing cholangitis, primary biliary cholangitis and overlap syndromes, drug-induced liver injury, hemochromatosis, Wilson's disease, α1-antitrypsin deficiency)
liver cirrhosis
any malignancy
chronic kidney disease
uncontrolled hypothyroidism or hyperthyroidism
use of the following medications within a 12-month period before baseline associated with drug-induced fatty liver: interferon, tamoxifen, amiodarone, aloperidin, glucocorticosteroids, anabolic steroids, any medication against tuberculosis, epilepsy or viruses, methotrexate, parenteral nutrition
use of the following medications within a 12-month period before baseline associated probably with improvement in fatty liver: vitamin E, pioglitazone, insulin, glucagon-like peptide-1 receptor agonists (GLP-1RAs), sodium-glucose co-transporter-2 inhibitors (SGLT-2), orlistat, ursodeoxycholic acid
use of any anti-osteoporotic medication within a 12-month period before baseline, except for calcium and vitamin D
Clareo Health | Effect of Anti-osteoporotic Medications on Nonalcoholic Fatty Liver Disease
